Mediastinal fibrosis is a rare disease of diverse etiologies, but sometimes idiopathic. Its evolution is progressive and its complications depend on the structures it compresses. Vascular compressions may lead to superior vena cava syndrome, and pulmonary hypertension. Surgery and endovascular treatment may be effective, but often need to be repeated. Systemic treatments, including corticosteroids, have variable responses.
We present an original case of mediastinal fibrosis, compressing the superior vena cava, the right pulmonary artery, and upper right pulmonary vein. For a 6 year follow up, the patient did not present pulmonary hypertension but only superior vena cava syndrome which was effectively treated by endovascular stenting. Systemic corticosteroids were not very effective for the improvement of symptoms. Later, the patient was treated with chemotherapy and immunosuppressive drugs for acute myeloid leukaemia. His respiratory, cardiovascular and imaging exams revealed stability which led us to reflect on the possible impact of the immunosuppressive therapy on the evolution of this mediastinal fibrosis.
Keywords: Endovascular stenting, mediastinal stenosis, triple vascular stenosis, surgery, endovascular treatment.
Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Synthesis and Anticancer Activity of Some 1H-inden-1-one Substituted (Heteroaryl)Acetamide Derivatives
Letters in Drug Design & Discovery Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Structural and Functional Role of Gly281 in L-asparaginase from Erwinia carotovora
Protein & Peptide Letters Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Medicinal Chemistry Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry In or Out Stemness: Comparing Growth Factor Signalling in Mouse Embryonic Stem Cells and Primordial Germ Cells
Current Stem Cell Research & Therapy Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms
Current Medicinal Chemistry Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Formulation Optimization of Etoposide Loaded PLGA Nanoparticles by Double Factorial Design and their Evaluation
Current Drug Delivery Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality
Reviews on Recent Clinical Trials Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Anti-Cancer Agents in Medicinal Chemistry OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry